Whole Body Positron Emission Tomography in Oncology
It has been shown in numerous studies that malignant tumors can be identified by increased trapping of 18F fluorodeoxyglucose (FDG) . The reported sensitivity of positron-emission-tomography (PET) with FDG varies between 80–90%. Until 1993 the maximum field of view (FOV) of commercially available PET-scanners was 5–10 cm confining the use of PET to defined body regions. Recently high resolution PET-scanners with 15 cm FOV have been developed. Sequential scanning of 5–11 FOV’s allows to perform whole body (WB) scans - head to knee or head to foot - in 30–55 minutes (Fig.1) taking maximum profit of the favourable properties of FDG for tumor diagnosis and staging.
KeywordsThyroid Cancer Bone Metastasis Thyroid Carcinoma Differentiate Thyroid Cancer Follicular Adenoma
Unable to display preview. Download preview PDF.
- 2.Tse NY, Hawkins RA, Zimmer MJ, Dahlbaum M, et al 1992.:The application of positron emission tomography imaging with fluorodeoxygluose to the evaluation of breast disease. AnnSurg 1992, 216 (1): 27–34.Google Scholar
- 6.Karlan BY, Hawkins R, Hoh CK, Lee M et al: Whole body positron emission tomography with 2–18 F fluor-desoxyglucose can detect recurrent ovarian carcinoma. Gynecol. Oncol 1993, 51 (2): 175–181.Google Scholar
- 7.Yao WJ, Hoh CK, Glapsy JA, et al: Whole body FDG PET imaging for staging ofmalignant melanoma. J.Nucl Med. 1994; 34: 8 P.Google Scholar
- 11.Bömer AR, Voth E, Schicha H. 18-FDG-PET bei Patienten mit immunogener Hyper thyreose vor Radiojodtherapie. Nucl.Med. 1994, 33 A 81.Google Scholar